← Patent-cliff monitor small molecule CAPLYTA LUMATEPERONE TOSYLATE
Loss of exclusivity December 2040 latest FDA-listed patent expiry
Drug detail Brand name CAPLYTA Active ingredient LUMATEPERONE TOSYLATE Strength EQ 21MG BASE Dosage form CAPSULE Route ORAL Modality Small molecule FDA approval April 2022 Marketing status RX
Listed patents Patent Expires Type 11753419 December 2040 product 12410195 December 2040 product 12122792 December 2040 product 11980617 October 2039 use U-3940 10695345 August 2039 product 11806348 August 2039 product 11690842 August 2039 product 11052084 August 2039 product 12409176 March 2039 use U-4261 9956227 December 2034 use U-2714 11026951 December 2034 use U-3364 RE48839 August 2033 use U-3271 8648077 December 2029 substance, product 9616061 May 2029 product 10117867 May 2029 use U-3271 9199995 March 2029 use U-2713 RE48825 March 2029 substance 10464938 March 2028 product
Regulatory exclusivity Code Expires M-319 April 2029 I-904 November 2028
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.